Your session is about to expire
← Back to Search
This trial will test a new drug to see if it can help people with diabetic neuropathic pain, over a 24wk period with 3 study periods.
- Diabetic Neuropathy
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2021 Phase 2 trial • 202 Patients • NCT04627038
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has the regulator granted permission for LY3556050 Dose 1 to be utilized?
"As a Phase 2 trial, LY3556050 Dose 1 has some data demonstrating its safety but not yet any evidence of efficacy. Therefore, we have rated it a 2 on our scale from 1 to 3."
How many healthcare facilities are conducting this experiment?
"55 sites are participating, including Headlands Research - Scottsdale in Scottsdale, Orange Grove Family Practice in Tucson, and Preferred Research Partners in Little Rock."
Is participation in this experiment still available for individuals?
"The information found on clinicaltrials.gov suggests that this trial is not recruiting anymore, with the original posting dated October 6th 2023 and last edit being on October 3rd 2023. However, there are 291 other trials seeking participants at present."
Who else is applying?
What portion of applicants met pre-screening criteria?
What site did they apply to?
Why did patients apply to this trial?
Share this study with friends